14. Selonsertib

Gilead Sciences’ ASK1 inhibitor selonsertib was viewed as a front-runner in the challenging nonalcoholic steatohepatitis category until it hit a wall this year, missing the mark in a pair of phase 3 trials that spelled the end of the program.
Gilead Sign

Gilead | Selonsertib, firsocostat and cilofexor

Gilead’s selonsertib was among the front-runners of the NASH race until it failed in a pair of phase 3 studies. But selonsertib’s journey is far from over. The company is testing it alongside firsocostat and cilofexor, drugs it picked up from Nimbus Therapeutics and Phenex Pharmaceuticals, respectively, in a phase 2 study.